Eben Tessari - Jul 15, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Jul 15, 2025
Transactions value $
-$3,004,964
Form type
4
Date filed
8/7/2025, 04:40 PM
Previous filing
Jul 16, 2025
Next filing
Aug 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tessari Eben CHIEF OPERATING OFFICER 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Madelyn Zeylikman, Attorney-in-Fact 2025-08-07 0001867899

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Award $11.8K +752 +1.53% $15.63 49.9K Jul 15, 2025 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise $403K +38.9K +77.99% $10.36 88.8K Aug 5, 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $395K +30.4K +34.27% $12.97 119K Aug 5, 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $363K +32.7K +27.42% $11.10 152K Aug 5, 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $310K +25.9K +17.04% $11.97 178K Aug 5, 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $114K +10.6K +5.98% $10.76 189K Aug 5, 2025 Direct F2
transaction KNSA Class A Ordinary Share Sale -$4.58M -138K -73.23% $33.20 50.5K Aug 5, 2025 Direct F2, F3
transaction KNSA Class A Ordinary Share Sale -$18.6K -550 -1.09% $33.90 49.9K Aug 5, 2025 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -38.9K -100% $0.00 0 Aug 5, 2025 Class A Ordinary Share 38.9K $10.36 Direct F2, F5
transaction KNSA Share Option Options Exercise $0 -30.4K -64.58% $0.00 16.7K Aug 5, 2025 Class A Ordinary Share 30.4K $12.97 Direct F2, F6
transaction KNSA Share Option Options Exercise $0 -32.7K -50% $0.00 32.7K Aug 5, 2025 Class A Ordinary Share 32.7K $11.10 Direct F2, F7
transaction KNSA Share Option Options Exercise $0 -25.9K -39.58% $0.00 39.5K Aug 5, 2025 Class A Ordinary Share 25.9K $11.97 Direct F2, F8
transaction KNSA Share Option Options Exercise $0 -10.6K -25% $0.00 31.9K Aug 5, 2025 Class A Ordinary Share 10.6K $10.76 Direct F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2025 to July 15, 2025. The acquisition of these shares was exempt pursuant to Rule 16B-3(e).
F2 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.83 and $33.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.83 and $33.98. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 The option is fully vested and exercisable.
F6 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
F7 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
F8 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
F9 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.